HI
SVA

Horizon Investments’s Sinovac Biotech, Ltd SVA Stock Holding History

Horizon Investments’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$673 Buy
104
+52
+100% +$337 ﹤0.01% 1341
2025
Q4 		$336 Hold
52
– – ﹤0.01% 1281
2025
Q3 		$336 Hold
52
– – ﹤0.01% 1155
2025
Q2 		$336 Buy
+52
New +$336 ﹤0.01% 1092
2024
Q4 		– Sell
-52
Closed -$336 – 936
2024
Q3 		$336 Hold
52
– – ﹤0.01% 825
2024
Q2 		$336 Hold
52
– – ﹤0.01% 812
2024
Q1 		$336 Hold
52
– – ﹤0.01% 796
2023
Q4 		$336 Hold
52
– – ﹤0.01% 785
2023
Q3 		$336 Hold
52
– – ﹤0.01% 743
2023
Q2 		$336 Buy
+52
New +$336 ﹤0.01% 718

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Horizon Investments's SVA Position: Q1 2026 in Review

Horizon Investments increased its Sinovac Biotech, Ltd (SVA) stake by 100% in Q1 2026, buying an estimated $337 and bringing the position to 104 shares worth $673. The position accounts for ﹤0.01% of the portfolio, ranked #1341.

Horizon Investments first reported a position in SVA in Q2 2023 and has held it in 10 quarters since. 28 funds tracked by Wall St. Rank hold SVA as of Q1 2026.

  • Horizon Investments held 104 shares of Sinovac Biotech, Ltd worth $673 as of Q1 2026.
  • Horizon Investments bought 52 Sinovac Biotech, Ltd shares in Q1 2026, an estimated $337.
  • Sinovac Biotech, Ltd made up ﹤0.01% of Horizon Investments's portfolio in Q1 2026, its #1341 holding.
  • Horizon Investments first reported a position in Sinovac Biotech, Ltd in Q2 2023 and has held it in 10 quarters since.
  • 28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2026.

Based on Horizon Investments's 13F filing for Q1 2026, filed 15 May 2026.